Mesa Laboratories MLAB Gain (Loss), Foreign Currency Transaction, before Tax

Gain (Loss), Foreign Currency Transaction, before Tax at other companies

3MMMM

——

Bio-Rad LaboratoriesBIO

——

Sotera HealthSHC

——

AbbottABT

——

Other financials

Income statement

See full

Revenue$63.7M+2.6%

Gross profit$31.2M-0.5%

Operating income-$664.0K+85.5%

Net income$3.6M+317%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$26.9M-1.4%

Total debt$78.7M-53.1%

Total equity$186.2M+16.5%

Total assets$427.7M-1.3%

Cash flow

See full

Operating cash flow$14.0M+10.2%

CapEx$417.0K-44.9%

Free cash flow$13.5M+13.7%

Valuation

See full

Market cap$542.27M+3.7%

Enterprise value$594.05M-10.4%

P/S2.2×0.0×

Profitability

See full

Gross margin56.8%—

Operating margin2.3%—

Net margin1.5%+0.8pp

FCF margin15.9%-1.8pp

Returns & leverage

See full

Return on equity2.2%+1.1pp

Debt / equity0.4×-0.6×

Current ratio1.7×+1.1×

Where this comes from

Reported directly by Mesa Laboratories in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.

The official record: Mesa Laboratories’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Mesa Laboratories's gain (loss), foreign currency transaction, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Mesa Laboratories's gain (loss), foreign currency transaction, before tax?: Mesa Laboratories (MLAB) reported gain (loss), foreign currency transaction, before tax of $95K in Q3 2025.
How has Mesa Laboratories's gain (loss), foreign currency transaction, before tax changed year-over-year?: Mesa Laboratories's gain (loss), foreign currency transaction, before tax decreased by 97.4% year-over-year, from $3.71M to $95K.